Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ

Neurochemical Research

Volumn 21, Issue 11, 1996, Pages 1387-1396

  Devine, Darragh P ^a   Taylor, Larry ^a   Reinscheid, Rainer K ^b   Monsma Jr , Frederick J ^b   Civelli, Olivier ^b   Akil, Huda ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

locomotion; nociceptin; opioid receptors; orphan receptor; Orphanin FQ; tolerance

Indexed keywords

NEUROPEPTIDE; NOCICEPTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; GAIT DISORDER; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR CONTROL; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; RAT; REARING;

ANIMALIA;

EID: 0029856934     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02532380     Document Type: Article

References (77)

1. Bunzow, J. R., Saez, C., Mortrud, M., Bouvier, C., Williams, J. T., Low, M., and Grandy, D. K. 1994. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, ∂ or κ opioid receptor type. FEBS Lett. 347:284-288.
2. Mollereau, C., Parmentier, M., Mailleux, P., Butour, J.-L., Moisand, C., Chalon, P., Caput, D., Vassart, G., and Meunier, J.-C. 1994. ORL1, a novel member of the opioid receptor family - Cloning, functional expression and localization. FEBS Lett. 341:33-38.
3. Wick, M. J., Minnerath, S. R., Lin, X., Elde, R., Law, P.-Y., and Loh, H. H. 1994. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned μ, ∂, and κ opioid receptors. Molec. Brain Res. 27:37-44.
4. Chen, Y., Fan, Y., Liu, J., Mestek, A., Tian, M., Kozak, C. A., and Yu, L. 1994. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 347:279-283.
5. Fukuda, K., Kato, S., Mori, K., Nishi, M., Takeshima, H., Iwabe, N., Miyata, T., Houtani, T., and Sugimoto, T. 1994. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 343:42-46.
6. Lachowicz, J. E., Shen, Y., Monsma, F. J., Jr., and Sibley, D. R. 1995. Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. J. Neurochem. 64:34-40.
7. Wang, J. B., Johnson, P. S., Imai, Y., Persico, A. M., Ozenberger, B. A., Eppler, C. M., and Uhl, G. R. 1994. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett. 348:75-79.
8. Nishi, M., Takeshima, H., Mori, M., Nakagawara, K.-I., and Takeuchi, T. 1994. Structure and chromosomal mapping of genes for the mouse κ-opioid receptor and an opioid receptor homologue (MOR-C). Biochem. Biophys. Res. Commun. 205:1353-1357.
9. Chen, Y., Mestek, A., Liu, J., Hurley, J. A., and Yu, L. 1993. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Molecular Pharmacology 44:8-12.
10. Minami, M., Onogi, T., Toya, T., Katao, Y., Hosoi, Y., Maekawa, K., Katsumata, S., Yabuuchi, K., and Satoh, M. 1994. Molecular cloning and in situ hybridization histochemistry for rat μ-opioid receptor. Neurosci. Res. 18:315-322.
11. Thompson, R. C., Mansour, A., Akil, H., and Watson, S. J. 1993. Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron 11:903-913.
12. Evans, C. J., Keith, D. E., Jr., Morrison, H., Magendzo, K., and Edwards, R. H. 1992. Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955.
13. Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., and Hirth, C. G. 1992. The d-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89:12048-12052.
14. Meng, F., Xie, G.-X., Thompson, R. C., Mansour, A., Goldstein, A., Watson, S. J., and Akil, H. 1993. Cloning and pharmacological characterization of a rat κ opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 90:9954-9958.
15. Minami, M., Toya, T., Katao, Y., Maekawa, K., Nakamura, S., Onogi, T., Kaneko, S., and Satoh, M. 1993. Cloning and expression of a cDNA for the rat κ-opioid receptor. FEBS Lett. 329: 291-295.
16. Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., Jr., and Civelli, O. 1995. Orphanin FQ: A neuropeptide that activates an opioidlike G-protein-coupled receptor. Science 270:792-794.
17. 1 receptor. Nature 377:532-535.
18. Devine, D. P., Reinscheid, R., Monsma, F., Civelli, O., and Akil, H. 1996. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 727:225-229.
19. Shuster, L., Webster, G. W., and Yu, G. 1975. Increased running response to morphine in morphine-pretreated mice. J. Pharmacol. Exp. Ther. 192:64-72.
20. Johnson, D. W., and Click, S. D. 1993. Dopamine release and metabolism in nucleus accumbens and striatum of morphine-tolerant and nontolerant rats. Pharmacol. Biochem. Behav. 46:341-347.
21. Di Chiara, G., and Imperato, A. 1988. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1067-1080.
22. Amalric, M., and Koob, G. F. 1985. Low doses of methylnaloxonium in the nucleus accumbens antagonize hyperactivity induced by heroin in the rat. Pharmacol. Biochem. Behav. 23:411-415.
23. Meyer, M. E., and Meyer, M. E. 1993. Behavioral effects of opioid peptide agonists DAMGO, DPDPE, and DAKLI on locomotor activities. Pharmacol. Biochem. Behav. 45:315-320.
24. 2), a potent μ-opioid peptide agonist, affects various patterns of locomotor activities. Pharmacol. Biochem. Behav. 51:149-151.
25. Chang, K.-J., Rigdon, G. C., Howard, J. L., and McNutt, R. W. 1993. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J. Pharmacol. Exp. Ther. 267:852-857.
26. Michael-Titus, A., Dourmap, N., and Costentin, J. 1989. Mu and delta opioid receptors control differently the horizontal and vertical components of locomotor activity in mice. Neuropeptid. 13: 235-242.
27. Ukai, M., Yamada, S., and Kameyama, T. 1984. Naloxone reverses the inhibitory effects of dynorphin A on motor activity in the mouse. Pharmacol. Biochem. Behav. 20:815-818.
28. Trujillo, K. A., and Akil, H. 1991. Opioid and non-opioid behavioral actions of dynorphin A and the dynorphin analogue DAKLI. NIDA Res. Mono. 105:397-398.
29. Leyton, M., and Stewart, J. 1992. The stimulation of central κ opioid receptors decreases male sexual behavior and locomotor activity. Brain Res. 594:56-74.
30. Jackson, A., and Cooper, S. J. 1986. An observational analysis of the effect of the selective kappa opioid agonist, U-50,488H, on feeding and related behaviours in the rat. Psychopharmacol. 90: 217-221.
31. von Voightlander, P. F., Lahti, R. A., and Ludens, J. H. 1983. U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224:7-12.
32. Post, R. M. 1980. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci. 26:1275-1282.
33. Kalivas, P. W., and Duffy, P. 1987. Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J. Pharmacol. Exp. Ther. 241:204-212.
34. Bartoletti, M., Gaiardi, M., Gubellini, G., Bacchi, A., and Babbini, M. 1983. Long-term sensitization to the excitatory effects of morphine. A motility study in post-dependent rats. Neuropharmacol. 22:1193-1196.
35. Moghaddam, B., and Bunney, B. S. 1989. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J. Neurochem. 53:652-654.
36. Guyton, A. C. 1981. Textbook of Medical Physiology. Page 441. W. B. Saunders Co., Philadelphia.
37. Johnson, A. K., and Epstein, A. N. 1975. The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin. Brain Res. 86:399-418.
38. Calcagnetti, D. J., and Holtzman, S. G. 1991. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol. Biochem. Behav. 38: 185-190.
39. Tuli, J. S., Smith, J. A., and Morton, D. B. 1995. Stress measurements in mice after transportation. Laboratory Animals 29:132-138.
40. Seggie, J. A., and Brown, G. M. 1975. Stress response patterns of plasma corticosterone, prolactin, and growth hormone in the rat, following handling or exposure to a novel environment. Can. J. Physiol. Pharmacol. 53:629-637.
41. Morimoto, A., Nakamori, T., Morimoto, K., Tan, N., and Murakami N. 1993. The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats. J. Physiol. 460:221-229.
42. Piazza, P. V., Deminiere, J.-M., Le Moal, M., and Simon, H. 1989. Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511-1513.
43. Nothacker, H.-P., Reinscheid, R. K., Mansour, A., Henningsen, R. A., Ardati, A., Monsma, F. J., Jr., Watson, S. J., and Civelli, O. 1996. Primary structure and tissue distribution of the orphanin FQ precursor. Proc. Natl. Acad. Sci. U.S.A. (In Press)
44. Kalivas, P. W., Taylor, S., and Miller, J. S. 1985. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. 1. Behavioral characterization. J. Pharmacol. Exp. Ther. 235:537-543.
45. Holmes, L. J., and Wise R. A. 1985. Contralateral circling induced by tegmental morphine: anatomical localization, pharmacological specificity, and phenomenology. Brain Res. 326:19-26.
46. Kelley, A. E., Stinus, L., and Iversen, S. D. 1980. Interactions between D-Ala-Metenkephalin, A10 dopaminergic neurones, and spontaneous behavior in the rat. Behav. Brain Res. 1:3-24.
47. 5]enkephalin. Brain Res. 450:382-386.
48. Daugé, V., Kalivas, P. W., Duffy, T., and Roques, B. P. 1992. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. Brain Res. 599:209-214.
49. Latimer, L. G., Duffy, P., and Kalivas, P. W. 1987. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J. Pharmacol. Exp. Ther. 241: 328-337.
50. Broekkamp, C. L. E., Phillips, A. G., and Cools, A. R. 1979. Stimulant effects of enkephalin microinjection into the dopaminergic A10 area. Nature 278:560-562.
51. Kalivas, P. W., Widerlöv, E., Stanley, D., Breese, G., and Prange, A. J., Jr. 1983. Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmacol. Exp. Ther. 227:229-237.
52. Joyce, E. M., and Iversen, S. D. 1979. The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci. Lett. 14:207-212.
53. Kalivas, P. W. 1985. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. H. Involvement of the mesolimbic dopamine system. J. Pharmacol. Exp. Ther. 235:544-550.
54. Vezina, P., and Stewart, J. 1984. Conditioning and place-specific sensitization of increases in activity induced by morphine in the VTA. Pharmacol. Biochem. Behav. 20:925-934.
55. Calenco-Choukroun, G., Daugé, V., Gacel, G., Féger, J., and Roques, B. P. 1991. Opioid 9 agonists and endogenous enkephalins induce different emotional reactivity than m agonists after injection in the rat ventral tegmental area. Psychopharmacol. 103: 493-502.
56. Kalivas, P. W., and Richardson-Carlson, R. 1986. Endogenous enkephalin modulation of dopaminergic neurons in the ventral tegmental area. Am. J. Physiol. 251:R243-R249.
57. Vezina, P., and Stewart, J. 1989. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res. 499: 108-120.
58. Kalivas, P. W., and Duffy, P. 1990. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J. Neurosci. 10:2940-2949.
59. Cunningham, S. T., and Kelley, A. E. 1992. Opiate infusion into nucleus accumbens: contrasting effects on motor activity and responding for conditioned reward. Brain Res. 588:104-114.
60. Churchill, L., and Kalivas, P. W. 1992. Dopamine depletion produces augmented behavioral responses to a mu-, but not delta-opioid receptor agonist in the nucleus accumbens: lack of a role for receptor upregulation. Synapse 11:47-57.
61. Meyer, M. E., McLaurin, B. I., Allen, M., and Meyer, M. E. 1994. Diphasic effects of intraacumbens μ-opioid peptide agonist DAMGO on locomotor activities. Pharmacol. Biochem. Behav. 47:827-831.
62. Daugé, V., Rossignol, P., and Roques, B. P. 1988. Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective μ and ∂ opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes. Psychopharmacol. 96:343-352.
63. Austin, M. C., and Kalivas, P. W. 1990. Enkephalinergic and GA-BAergic modulation of motor activity in the ventral pallidum. J. Pharmacol. Exp. Ther. 252:1370-1377.
64. Klitenick, M. A., and Kalivas, P. W. 1994. Behavioral and neurochemical studies of opioid effects in the pedunculopontine nucleus and mediodorsal thalamus. J. Pharmacol. Exp. Ther. 269: 437-448.
65. Klitenick, M. A., and Wirtshafter, D. 1995. Behavioral and neurochemical effects of opioids in the paramedian midbrain tegmentum including the median raphe nucleus and ventral tegmental area. Journal of Pharmacology and Experimental Therapeutics 273:327-336.
66. Vezina, P., Kalivas, P. W., and Stewart, J. 1987. Sensitization occurs to the locomotor effects of morphine and the specific μ opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res. 417:51-58.
67. Long, J. B., Mobley, W. C., and Holaday, J. W. 1988. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. I. Injection procedures modify pharmacological responses. J. Pharmacol. Exp. Ther. 246:1158-1166.
68. Long, J. B., Petras, J. M., Mobley, W. C., and Holaday, J. W. 1988. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory, and autonomie functions. J. Pharmacol. Exp. Ther. 246:1167-1174.
69. Reinscheid, R. K., Ardati, A., Monsma, F. J., Jr., and Civelli, O. 1996. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 271:14163-14168.
70. Jacquet, Y. F., and Marks, N. 1976. The C-fragment of β-lipotropin: an endogenous neuroleptic or antipsychotogen? Science 194: 632-635.
71. Bloom, F., Segal, D., Ling, N., and Guillemin, R. 1976. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194:630-632.
72. Segal, D. S., Brown, R. G., Bloom, F., Ling, N., and Guillemin, R. 1977. β-endorphin: endogenous opiate or neuroleptic? Science 198:411-414.
73. Chang, J.-K., and Fong, B. T. W. 1976. Opiate receptor affinities and behavioral effects of enkephalin: structure-activity relationship often synthetic peptide analogues. Life Sci. 18:1473-1482.
74. Büscher, H. H., Hill, R. C., Römer, D., Cardinaux, F., Closse, A., Hauser, D., and Pless J. 1976. Evidence for analgesic activity of enkephalin in the mouse. Nature 261:423-425.
75. Belluzzi, J. D., Grant, N., Garsky, V., Sarantakis, D., Wise, C. D., and Stein L. 1976. Analgesia induced in vivo by central administration of enkephalin in rat. Nature 260:625-626.
76. Deakin, J. F. W., Dostrovsky, J. O., and Smyth, D. G. 1980. Influence of N-terminal acetylation and C-terminal proteolysis on the analgesic activity of beta-endorphin. Biochem. J. 189:501-506.
77. Akil, H., Young, E., Watson, S. J., and Coy, D. H. 1981. Opiate binding properties of naturally occurring N- and C-terminus modified beta-endorphins. Peptides 2:289-292.